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Objectives: Staphylococcus aureus is a notorious bacterial pathogen and antibiotic-resistant isolates complicate
current treatment strategies. We characterized S. aureus VC40, a laboratory mutant that shows full resistance to
glycopeptides (vancomycin and teicoplanin MICs ≥32 mg/L) and daptomycin (MIC¼4 mg/L), to gain deeper
insights into the underlying resistance mechanisms.
Methods:Genomics and transcriptomics were performed to characterize changes that might contribute to devel-
opment of resistance. The mutations in vraS were reconstituted into a closely related parental background. In
addition, antimicrobial susceptibility testing, growth analyses, transmission electron microscopy, lysostaphin-
induced lysis and autolysis assays were performed to characterize the phenotype of resistant strains.
Results: Genome sequencing of strain VC40 revealed 79 mutations in 75 gene loci including genes encoding the
histidine kinases VraS and WalK that control cell envelope-related processes. Transcriptomics indicated the
increased expression of their respective regulons. Although not reaching the measured MIC for VC40, reconstitu-
tion of the L114S and D242G exchanges in VraS(VC40) into the susceptible parental background (S. aureus NCTC
8325) resulted in increased resistance to glycopeptides and daptomycin. The expression of VraS(VC40) led to
increased transcription of the cell wall stress stimulon, a thickened cell wall, a decreased growth rate, reduced
autolytic activity and increased resistance to lysostaphin-induced lysis in the generated mutant.
Conclusions: We show that a double mutation of a single gene locus, namely vraS, is sufficient to convert the
vancomycin-susceptible strain S. aureus NCTC 8325 into a vancomycin-intermediate S. aureus.
Keywords: glycopeptides, teicoplanin, daptomycin, antibiotic resistance, two-component regulatory systems
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is among the
leading causes of mortality by any single infectious agent in the
USA and the European Union.1,2 The options for the treatment
of MRSA are limited. Since the early 1990s, vancomycin and
related glycopeptide antibiotics have been employed as therapy
for serious MRSA infections.3,4 However, S. aureus strains with
intermediate or full resistance to vancomycin emerged in recent
decades5 – 7 and clinical MRSA strains with additional resistance
to daptomycin and linezolid have been isolated.6,8,9 Since these
pathogens are able to sensitively respond to antibiotic stress,
it may be predicted that the resistance situation will not
substantially relax in the future.10,11 Understanding the bacterial
response to antibiotics as well as the established resistance
mechanisms to clinically used drugs is mandatory to evaluate
alternatives to commonly applied treatment strategies.
Here, we set out to characterize the vancomycin-resistant
laboratory mutant S. aureus VC40,12 which had previously been
generated by 30 serial passages of strain RN4220DmutS in the
presence of increasing concentrations of vancomycin.13 S. aureus
VC40 has a vancomycin MIC of 64 mg/L, a concentration higher
than the MIC for clinical vancomycin-intermediate S. aureus
(VISA) strains. Actually, the measured MIC for strain VC40 meets
the criteria for a vancomycin-resistant S. aureus (VRSA) strain
rather than for a VISA strain; however, it lacks the vanA gene
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cluster,12 which represents the common VRSA resistance deter-
minant.14 Comparative genomic and transcriptomic analyses of
S. aureus VC40 revealed non-synonymous single nucleotide poly-
morphisms (SNPs) in the sensor histidine kinase genes vraS and
walK as well as significantly altered expression levels of their
respective regulons. We reconstituted VraS(VC40) into the paren-
tal background (S. aureus NCTC 8325), characterized the expres-
sion of the respective regulon via quantitative real-time PCR
(qRT–PCR) and examined the phenotypes of the different mutant
strains by transmission electron microscopy (TEM), autolysis
assays and growth behaviour studies to elucidate the specific
role of VraS in antibiotic resistance. Our data show that VraS is a
central factor in S. aureus NCTC 8325 that can confer reduced sus-
ceptibilities to clinically applied drugs including the last-resort
antibiotics vancomycin and daptomycin.
Materials and methods
Strains, plasmids and growth conditions
Bacterial strains and plasmids are listed in Table S1 (available as
Supplementary data at JAC Online). Unless otherwise indicated, S. aureus
strains were grown in brain heart infusion (BHI) broth or Mueller–Hinton
(MH) broth (Oxoid) and Escherichia coli strains were grown in lysogeny
broth at 378C or 308C when using temperature-sensitive plasmids. For
plasmid maintenance, the required media were supplemented with ampi-
cillin (50 mg/L) or erythromycin (25 mg/L).
Growth curve analyses and antimicrobial
susceptibility testing
For growth curve analyses, three parallel cultures of the desired S. aureus
strains were grown at 378C in BHI or MH broth with or without the addition
of antibiotics in 96-well polystyrene round-bottomed microplates
(Greiner). The optical density at 600 nm (OD600) was monitored kinetically
using the Tecan SunriseTM plate reader equipped with an incubation cham-
ber (Tecan Group). The microplate was read every 10 min for 8 h with shak-
ing in between and prior to every read. The data were evaluated using
MagellanTM software (Tecan Group). MIC testing was performed using
the broth microdilution method in 96-well microplates with an inoculum
of 1×105–5×105 cfu/mL according to CLSI standards. Glycopeptide MICs
were evaluated in MH and BHI broth, since BHI is commonly used in vanco-
mycin susceptibility testing as it was described to be more sensitive for the
expression of the VISA type than MH.15 MICs were determined after 24 h
and after 48 h for the slowly growing strain VC40. For MIC determinations,
CaCl2 was added to the medium to a final concentration of 1.25 mM
for daptomycin (Cubicinw; Novartis Pharma) and friulimicin (MerLion
Pharmaceuticals) or 1 mM for mersacidin (Sanofi-Aventis).
Genome sequencing and identification of SNPs
Genome sequencing including gap closure of S. aureus RN4220DmutS
and S. aureus VC40 was performed as previously described.12 After contig
assembly, the resulting genome sequences were aligned against each
other as well as to the reference genome sequence of the closely related
S. aureus NCTC 8325 (NC_007795) using Mulan software (http://mulan.
dcode.org/). SNPs, insertions and deletions unique to S. aureus VC40 were
confirmed by Sanger sequencing. The genome sequence of S. aureus
VC40 was deposited in NCBI GenBank under accession number CP003033.12
Preparation of total RNA
Extraction of total RNA was done as previously described.16 Briefly, strains
were grown in BHI broth without addition of antibiotics to an OD600 of 1.0
and were then stabilized by incubation with RNAprotect (Qiagen) for 5 min
at 378C before harvesting. Cells were lysed in the presence of 200–
400 mg/L lysostaphin (Genmedics) and total RNA was extracted using
the PrestoSpin R bug Kit including DNase I treatment (Molzym). The quality
and quantity of total RNA were determined by agarose gel electrophoresis
and measured by using the Nanodrop spectrophotometer (Nanodrop
Technologies). For each strain, the RNA of at least two independently
grown cultures was analysed.
Microarray analyses
A validated S. aureus-specific microarray platform was employed contain-
ing 10807 60-mer oligonucleotide probes17,18 (Agilent Technologies)
covering .95% of ORFs annotated in strains N315, Mu50, MW2, COL,
NCTC 8325, USA300, MRSA252 and MSSA476 including their respective
plasmids. After DNase treatment of RNA samples, the absence of remain-
ing DNA was evaluated by qRT–PCR (SDS 7700; Applied Biosystems) as pre-
viously described.5,19 Cy3-dCTP-labelled cDNA was synthesized from 5 mg
batches of total RNA using SuperScript II reverse transcriptase (Invitrogen)
and was purified via QiaQuick columns (Qiagen). Microarrays were normal-
ized using Cy5-dCTP-labelled genomic DNA from the different sequenced
strains used for the microarray design as previously described.17,20 Cy5-
and Cy3-labelled cDNA mixtures were then diluted in 50 mL of Agilent
hybridization buffer and were hybridized at 608C for 17 h in a hybridization
oven (Robbins Scientific). Slides were washed, dried under nitrogen flow
and scanned using a microarray scanner (Agilent Technologies). The
microarray data were processed and evaluated as previously described17
and are posted in the Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo/) under accession numbers GPL10537 and
GSE46887.
qRT–PCR
Quantitative transcription data were obtained by measuring sample amp-
lification during the log-linear phase of the PCR using the Stratagene
Mx3005P instrument (Agilent Technologies). Total RNA preparations
(3 mg) were transcribed into cDNA using BioScript reverse transcriptase
(Bioline) and pd(N)6 random hexamers (GE Healthcare) as previously
described.16 qRT –PCR was performed using the Brilliant III Ultra-Fast
SYBRw Green QPCR Master Mix (Agilent Technologies). For all experiments,
the amount of transcripts was determined from the appropriate standard
curve and the target concentration was expressed in relation to the con-
centration of the constitutively expressed housekeeping gene gyrB. Each
standard curve was generated by assaying gene-specific PCR products.
For each strain, two different cDNA probes were synthesized employing
RNA preparations from independent cultures. The PCR products were veri-
fied by melting curve analyses. All qRT–PCR runs were at least performed
in duplicate.
Genetic manipulations of S. aureus
To reconstitute vraS of S. aureus VC40 into the susceptible parent strain
NCTC 8325, vraS(VC40) was cloned into the temperature-sensitive shuttle
vector pMAD that allows for markerless double homologous recombin-
ation.21 To this end, a PCR product spanning the T1973900C and
A1974284G mutations in vraS(VC40) was cloned into the pMAD vector
using the primers vraS_for (5′-ACCGAATTCATGACGCAATGTATTCGAA-3′)
and vraS_rev (5′-ATTGTCGACTCAATGGAAGGCGAAACAG-3′), thereby ge-
nerating pMAD-vraS(VC40), which was then electro-transformed into
S. aureus NCTC 8325 to finally yield S. aureus NCTC 8325 VraS(VC40)
after recombination had occurred. The presence of the vraS(VC40) muta-
tions after allelic exchange was confirmed by Sanger sequencing.
TEM
Strains were grown in BHI broth and cells were harvested in the exponen-
tial growth phase (OD600 of 1.0). Cells were fixed using 3% glutaraldehyde
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and 2% osmium tetroxide in 0.1 M sodium phosphate buffer (pH 7.2), fol-
lowed by a progressive dehydration and embedding in Epon resin
(Embed-812; Electron Microscopy Sciences). Ultrathin sections of 40–
60 nm were cut using an ultramicrotome (Leica) equipped with a diamond
knife (ultra 458; Diatome AG) and further contrasted using uranyl acetate
(3%) and lead citrate as described previously.22 The samples were visua-
lized using an EM 900 transmission electron microscope (Carl Zeiss
Microscopy) at magnifications of 30000- to 50000-fold.
S. aureus lysis assays
For Triton X-100-induced autolysis, cells were grown to the exponential
growth phase (OD600 of 1.0) and chilled on ice before harvesting. Cells
were washed once with ice-cold MilliQ ultrapure water (Merck Millipore)
and then resuspended to an OD600 of 1.0 in 50 mM Tris-HCl buffer contain-
ing 0.05% Triton X-100. Autolytic activity was measured during incubation
at 378C as a decrease in OD600 over time using a spectrophotometer
(UV-160; Shimadzu). For lysostaphin-induced lysis assays, strains were
grown to an OD600 of 1.0 and were then harvested by centrifugation.
Cells were washed with MilliQ water and resuspended to an OD600 of 0.8
in PBS including 200 ng/mL lysostaphin (Genmedics). Cell lysis was mea-
sured as described above.
Results
S. aureus VC40 shows decreased susceptibility to various
cell wall biosynthesis inhibitors
S. aureus VC40 could grow on agar plates containing vancomycin
at concentrations up to 40 mg/L as indicated by population ana-
lyses13 and it exhibited increased MICs of the glycopeptides
vancomycin and teicoplanin (≥32 mg/L), of the lipopeptides dap-
tomycin and friulimicin, of the lantibiotic mersacidin as well as of
several b-lactams (Table 1). Noteworthy, the MIC of daptomycin
reached 4 mg/L in strain VC40 and thus clearly exceeded the
MIC breakpoint for daptomycin susceptibility according to
EUCAST and CLSI criteria (resistant.1 mg/L). Obviously, S. aureus
VC40 had acquired specific mutations that affected the suscepti-
bilities to antibiotics with different individual targets, pointing at a
more universal resistance mechanism.
The S. aureus VC40 genome carries mutations that can be
linked to antibiotic resistance
Genome sequencing of S. aureus VC40 revealed a total of 79
mutations in 75 different loci compared with the genomes of its
parent strains RN4220DmutS, RN4220 and NCTC 8325,12,23 – 25
including 52 SNPs, 14 deletions and 13 insertions. The SNPs
could be divided into 34 non-synonymous SNPs, 13 synonymous
SNPs and 5 intergenic SNPs. The mutated gene loci comprised
regulatory genes (e.g. vraS and walK), genes related to cell enve-
lope metabolism and transport (e.g. lytD/SAOUHSC_01895, ssaA,
mraZ, vraG and mprF), chaperone-like genes (e.g. prsA, dnaK
and clpX) and genes related to cell metabolism (e.g. relP/
SAOUHSC_02811, rpoD and glmM). A complete list of the detected
mutations in S. aureus VC40 is presented in Table S2.
Increased expression of the VraSR and WalKR regulons
in S. aureus VC40
We compared the gene expression levels of untreated S. aureus
VC40 with those of its parent strain RN4220DmutS during the
exponential growth phase using S. aureus full genome micro-
arrays. Here, strain VC40 showed an increased expression of the
cell wall stress genes vraS, sgtB, cwrA, fmtA, murZ and tcaA
(Table 2). Two genes that have been reported to be coregulated
with the cell wall stress stimulon showed transcription levels
that were opposite to those expected from published results, as
the expression of atlA was increased and that of prsA was
decreased, and sle1 showed no difference in regulation between
strains VC40 and RN4220DmutS. The 2-fold increased transcrip-
tion of atlA might be explained by the result that the WalKR reg-
ulon genes are up-regulated in strain VC40 as well, e.g. sceD and
ssaA showed higher transcript levels in strain VC40 (Table S3). The
expression of genes controlled by VraS and/or WalK was also con-
firmed by qRT–PCR (Figure 1). Furthermore, various genes involved
in the transport and metabolism of carbohydrates, amino acids
and nucleotides were divergently expressed. For example, genes
of the lactose, histidine and urease operons exhibited higher tran-
script levels in strain VC40. Moreover, genes encoding serine pro-
teases (splABCDEF), cysteine protease (sspBC) as well as the ABC
transporter encoding genes vraFG and vraDE were more highly
expressed in strain VC40. In contrast, the cidAB genes, encoding
positive modulators of autolysin activity, showed significantly
decreased expression. The expression of genes encoding riboso-
mal proteins, amino-acyl-tRNA synthetase genes, F1Fo ATP syn-
thase genes (atpABCDEFGH) and other genes of the respiratory
chain such as the succinate dehydrogenase genes (sdhABC) was
also lower in strain VC40, thereby resembling the expression pat-
tern of the stringent response of S. aureus.
Table 1. Susceptibility testing of S. aureus NCTC 8325 derivatives used in this study
NCTC 8325 derivative
MIC (mg/L)a
VAN TEC DAP OXA LEX FOX CTX MER FRI
wild-type 0.75 (1.5) 0.5 (0.5) 0.25 0.19 2 1.5 0.75 8 1.5
RN4220DmutS 0.75 (1.5) 0.5 (1) 0.25 0.25 1.5 2 1 8 1
VC40 48 (64) 32 (48) 4 1 8 8 4 64 4
VraS(VC40) 3 (4) 6 (6) 2 0.5 6 4 1 32 2
VAN, vancomycin; TEC, teicoplanin; DAP, daptomycin; OXA, oxacillin; LEX, cefalexin; FOX, cefoxitin; CTX, cefotaxime; MER, mersacidin; FRI, friulimicin.
aMICs in MH; numbers in parentheses represent the vancomycin and teicoplanin MICs in BHI. MICs were read after 24 and 48 h considering the slow
growth of strain VC40. Noteworthy, MIC values for NCTC 8325 wild-type, RN4220DmutS and NCTC 8325 VraS(VC40) were unchanged after 24 and 48 h.
MIC values represent the mean of at least four independent determinations.
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Mutations in vraS affect antibiotic resistance in S. aureus
The L114S and D242G exchanges in VraS(VC40) were reconsti-
tuted into the genome of S. aureus NCTC 8325, the parental
background of strain VC40. Although not reaching the high
MIC values of S. aureus VC40, the resulting mutant, S. aureus
NCTC 8325 VraS(VC40), was characterized by an increased MIC
of vancomycin (MIC of 3 mg/L in MH broth and 4 mg/L in BHI
broth), teicoplanin (MIC of 6 mg/L in MH and BHI broths)
as well as daptomycin (MIC of 2 mg/L) (Table 1). Noteworthy,
the presence of VraS(VC40) also affected the susceptibilities to
the cell wall-active antibiotics mersacidin and different
b-lactams (Table 1). Reconstitution of the I544M exchange in
WalK was also attempted; however, despite repeated experi-
ments, the correct mutant was not obtained.
VraS(VC40) accounts for an increased expression
of the VraSR regulon
To study the gene regulatory impact of VraS(VC40) in strain NCTC
8325, we measured the relative transcript quantities of the vraS,
sgtB and lytM genes by qRT–PCR and, indeed, these genes were
more highly expressed in the S. aureus NCTC 8325 VraS(VC40)
mutant compared with its parent strain (Figure 1), indicating an
increased expression of the VraSR regulon. Noteworthy, we did
not observe a significant alteration of atlA expression in strain
NCTC 8325 VraS(VC40).
VraS(VC40) contributes to an altered phenotype
of S. aureus
In growth kinetic experiments, a strongly reduced growth rate of
S. aureus VC40 was observed compared with its parent strain
(Figure S1). The NCTC 8325 VraS(VC40) mutant was also charac-
terized by a slightly lowered growth rate (Figure S1), indicating
that VraS(VC40) might to some extent contribute to the low
growth rate observed for strain VC40. To gain further insights
into the morphologies of strain VC40 and the NCTC 8325
VraS(VC40) mutant, we performed TEM of exponentially growing
cells (Figure 2). Compared with the parent strains S. aureus NCTC
8325 (Figure 2d) and RN4220DmutS (Figure 2a), S. aureus VC40
was characterized by a significantly thickened cell wall with a
roughened surface and irregular appearance (Figure 2b and c).
Furthermore, a pseudomulticellular phenotype probably caused
by a retarded cell separation was observed in strain VC40, since
new septa were formed before the cell had completed the previ-
ous cell division event. Similarly, the thickness of the cell wall was
also increased in strain NCTC 8325 VraS(VC40) (Figure 2e and f).
Although the cell wall of the NCTC 8325 VraS(VC40) mutant also
displayed a more roughened and uneven surface, the pseudomul-
ticellular phenotype of strain VC40 was not observed here. The
measured cell wall thicknesses were 16.71 (+3.00) nm for strain
NCTC 8325 wild-type, 16.97 (+3.18) nm for strain RN4220DmutS,
62.36 (+13.98) nm for strain VC40 and 38.25 (+11.31) nm for the
NCTC 8325 VraS(VC40) mutant.
S. aureus strains VC40 and NCTC 8325 VraS(VC40) show
significantly reduced autolytic activities and an altered
susceptibility to lysostaphin
The autolytic activities of the S. aureus strains VC40 and NCTC
8325 VraS(VC40) were characterized by Triton X-100-induced
autolysis assays and were compared with their respective paren-
tal strains. Here, strains VC40 and NCTC 8325 VraS(VC40) both
exhibited a similarly severe reduction of autolytic activity
(Figure S2a). In addition, we determined lysostaphin-induced
lysis of the different strains over time (Figure S2b). Here, strains
RN4220DmutS and NCTC 8325 showed full susceptibility to lysos-
taphin treatment. Strain NCTC 8325 VraS(VC40) initially displayed
reduced cell lysis in the presence of lysostaphin, but the majority
of the cells were lysed after 60 min. Strikingly, strain VC40 was char-
acterized by a significantly increased resistance to lysostaphin.
Discussion
Genome sequencing of the vancomycin-resistant laboratory
mutant S. aureus VC40 identified SNPs in the histidine kinase
genes vraS and walK and we further investigated the impact of
VraS(VC40) on gene regulation, phenotypic characteristics and
antibiotic resistance. Mutations in regulatory genes are specifically
important, since these changes may alter the expression patterns
of large regulons and thus help the bacteria to adjust certain
Table 2. DNA microarray-based expression ratios of cell wall stress
stimulon genes including those under VraSR control26,27 of untreated
S. aureus strains VC40 versus RN4220DmutS
ORF
IDa Gene Comments
Ratio
VC40/
DmutS
00427 sle1 N-acetylmuramoyl-L-alanine amidase 0.90
00994 atlA bifunctional autolysin 2.09
00998 fmtA autolysis and methicillin
resistance-related protein
2.07
01838 htrA serine protease, heat-shock protein
homologue
2.02
01972 prsA peptidyl-prolyl cis/trans isomerase 0.32
02012 sgtB monofunctional glycosyltransferase 4.67
02099 vraS two-component sensor histidine
kinase
1.66
02100 yvqF/vraT conserved hypothetical protein 1.71
02101 hypothetical protein 2.12
02112 conserved hypothetical protein 1.71
02365 murZ UDP-N-acetylglucosamine
enolpyruvyl transferase
1.92
02583 similar to lyt divergon expression
attenuator LytR
1.90
02635 tcaA teicoplanin resistance-associated
protein
2.46
02723 glycerate kinase 4.09
02724 hypothetical protein 4.17
02811 relP putative (p)ppGpp synthetase 5.10
02872 cwrA CwrA protein, cell wall responsive
for antibiotics
21.32
aORF IDs correspond to ‘SAOUHSC_’ locus tags of S. aureus NCTC 8325
(NC_007795).
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Figure 1. Gene expression analyses of VraSR and WalKR regulon members. Transcript levels of vraS, sgtB, lytM, atlA, sceD and ssaA were determined by
qRT–PCR in relation to gyrB expression. Values represent the mean of results obtained for two independently grown cultures for each strain and are
representative for at least two separate qRT–PCR experiments.
(b) (c)(a)
(e) (f)(d)
Figure 2. Morphological analyses by transmission electron microscopy. Ultrathin sections of exponentially grown S. aureus strains RN4220DmutS (a),
VC40 (b and c), NCTC 8325 wild-type (d) and NCTC 8325 VraS(VC40) (e and f) were visualized. Scale bars represent 0.5 mm.
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physiological networks that allow them to counteract antibiotic
stress. In S. aureus VC40, the vraS gene harbours two non-
synonymous SNPs that lead to the amino acid exchanges L114S
and D242G in VraS. The introduction of these mutations into a
susceptible parental background resulted in noticeable MIC
increases of several cell wall-active antibiotics, including vanco-
mycin, teicoplanin and daptomycin. VraS is part of the VraSR two-
component regulatory system (TCRS) and conveys the so-called
cell wall stress response, which coordinates the regulation of
mostly cell wall biosynthesis-related genes such as sgtB or the
vraSR genes themselves.26 – 29 Various mutations in the vraSR/
yvqF(vraT) locus have been reported in VISA strains30 – 33 and,
interestingly, the location of the SNPs in vraSR/yvqF in different
strains is very diverse and there seems to be no specific hotspot
for mutations in certain domains of these genes.
Only a few of the SNPs in vraSR/yvqF have been further investi-
gated to elucidate their putative impact on gene regulation and
antibiotic resistance development so far.33,34 In our study,
VraS(VC40) was sufficient to convert the vancomycin-susceptible
strain S. aureus NCTC 8325 into a strain with a VISA type of resist-
ance. An earlier study described the effect of the I5N amino acid
exchange in VraS of strain Mu50.34 Here, the introduction of the
respective VraS(I5N) into the S. aureus Mu50V background com-
pared with the VraS wild-type showed a lower resistance increase
(MIC increase from 3.5 to 4.5 mg/L) compared with the effect that
is shown by VraS(VC40) in the NCTC 8325 background (MIC
increase from 0.75 to 3 mg/L).34 Furthermore, a study by
Gardete et al.33 detected a Y220C amino acid exchange in YvqF
in addition to mutations in vraG, yycH and lspA in strain SG-R, a
clinical VISA isolate of the USA300 clone, and identified YvqF as
a negative regulator of vraSR. However, a direct impact of
YvqF(Y220C) on vancomycin resistance could not be determined
by introducing the mutated yvqF gene on a plasmid into the
vancomycin-susceptible strain SG-S, which still harbours a
chromosomal copy of the wild-type yvqF gene. In contrast, the
introduction of a plasmid with the wild-type version of yvqF into
strain SG-R led to a decreased vancomycin MIC. In that study, a
chromosomal reconstitution of the yvqF mutation into strain
SG-S was not shown.33 Noteworthy, since the mutations in vraS
or yvqF mentioned above have each been reintroduced into differ-
ent strain backgrounds, a strain dependency of the observed
effects cannot be excluded.
In our study, the VraSR-controlled cell wall stress stimulon26,27
was characterized by a considerably increased expression in
S. aureus NCTC 8325 VraS(VC40) as well as in S. aureus VC40.
Remarkably, the lytM gene also showed a higher transcript level
in the NCTC 8325 VraS(VC40) mutant, which confirms the state-
ment by Gardete et al.33 that lytM appears to be an additional
member of the VraSR regulon. Obviously, the increased expression
of members of the VraSR regulon contributes to the observed
reduced susceptibility to vancomycin, teicoplanin, daptomycin,
mersacidin and oxacillin in our study. Noteworthy, these antibio-
tics have also been described to induce the VraSR regu-
lon.16,26,28,35,36 In this context, an accelerated peptidoglycan
biosynthesis, which may be mediated by an activated VraSR reg-
ulon, is likely to account for this decrease in antibiotic susceptibil-
ity by supplying an increased number of cell wall precursors or by a
faster incorporation of these precursors into the nascent peptido-
glycan meshwork, eventually also leading to a thickening of the
cell wall. Although commonly down-regulated upon vancomycin
treatment, we did not observe a significant alteration of atlA
expression in strain NCTC 8325 VraS(VC40), which is in accordance
with previous observations that the regulation of atlA is most
probably not mediated by VraSR.26 Of note, mutations in the
vraSR/yvqF genes are predominantly discussed regarding their
impact on vancomycin resistance. However, we detected a strong
influence of VraS(VC40) on daptomycin non-susceptibility, as the
daptomycin MIC for the NCTC 8325 VraS(VC40) mutant reached
2 mg/L. It has to be noted that despite the effect of the
vraS(VC40) mutations as well as the observation of Mehta
et al.37 concerning the contribution of deletion or up-regulation
of vraSR in daptomycin-non-susceptible strains, which share a sig-
nificant impact on daptomycin susceptibility, to our knowledge
daptomycin treatment has not been described to select for muta-
tions in the vraSR/yvqF operon so far.
An increased cell wall thickness as observed in strains VC40
and NCTC 8325 VraS(VC40) is likely to be a major contributor to
the increased resistance to glycopeptides and daptomycin of
these strains. Here, a cell wall thickness of 62 nm was reached
in strain S. aureus VC40 and 38 nm in strain NCTC 8325
VraS(VC40). Thickening of the cell wall has been previously
described as a common phenotypic feature of VISA strains6,38,39
and has also been related to daptomycin cross-resistance;40 how-
ever, the cell wall thickness of the typical VISA strain grown in BHI
does not exceed 35 nm.39 Noteworthy, up-regulation of the VraSR
regulon and concomitant thickening of the cell wall have also
been reported in daptomycin-non-susceptible S. aureus strains
that were generated by serial daptomycin selection and that add-
itionally showed a heterogeneous VISA phenotype.41 Our study
supports a prominent role of the VraSR regulon in the build-up
of a thickened cell wall in S. aureus. Although the up-regulation
of the cell wall biosynthesis machinery by VraSR and/or a possible
deregulation of the bacterial autolytic system by the exchange
present in WalKR in strain VC40 would both provide plausible
explanations for the accumulation of excess cell wall material,
the explicit mechanism that leads to cell wall thickening remains
unclear. Interestingly, the pseudomulticellular phenotype of
strain VC40 was not observed in strain NCTC 8325 VraS(VC40),
indicating that VraSR is at least not solely responsible for this phe-
nomenon and that probably more than one mutation may even-
tually lead to this phenotype in S. aureus VC40.
Although many of the autolysin genes including atlA were
more highly expressed in strain VC40, Triton X-100-induced
autolysis of strain VC40 was significantly decreased. This phenom-
enon has also been observed in the VISA strain JH9 and the
vancomycin-resistant mutant VP32;27,42,43 however, the reason
for this remained elusive. The similarly reduced autolytic activities
of strain NCTC 8325 VraS(VC40) and strain VC40 might indicate
that an activated VraSR regulon generates modifications in the
peptidoglycan structure of these strains, eventually leading to
an increased resistance against Triton X-100-induced autolysis.
In accordance with this assumption, it has previously been sug-
gested that quantitative (or qualitative) changes in the teichoic
acids of VISA strains might decrease peptidoglycan degradation
by autolytic enzymes.43 The clearly increased cell wall thickness
of strain VC40 most probably accounts for the more severe
decrease in lysostaphin susceptibility compared with strain NCTC
8325 VraS(VC40) and it may also play a role in the autolytic behav-
iour of the affected strains, but it is most likely not the sole factor
in resistance against Triton X-100-induced autolysis. Since the
Generation of a VISA strain by mutation of vraS
3195
JAC
strains in our study and other VISA strains share the common
phenotype of a reduced autolytic activity,6,43 – 47 this feature is
likely important for the development of resistance.
Strain NCTC 8325 VraS(VC40) did not reach the measured MICs
and cell wall thickness of strain VC40, indicating that additional
mutations add to the high level of resistance in the latter strain.
In addition to the role of VraS(VC40) in contributing to the devel-
opment of glycopeptide and daptomycin resistance described
above, we identified an SNP in the walK gene leading to an
I544M amino acid exchange located in the HATPase_c domain
of the histidine kinase in strain VC40. The WalKR TCRS is an essen-
tial master regulator in cell wall metabolism and homeostasis.48
Deregulation of this system may have important consequences
for the bacteria and might enforce further adaptive changes, i.e.
concerning membrane or cell wall composition. Microarray profil-
ing revealed an increased expression of the WalKR regulon in
S. aureus VC40 including the ssaA, lytM, sceD and atlA autolysin
genes, which have been described to be under direct positive
WalR control.49,50 Mutations in the walKR operon have previously
been linked to vancomycin or daptomycin non-susceptibility in
several studies;31,32,51 – 57 however, only a few of these have
been analysed concerning their effect on antibiotic resistance,
which might also be related to the complexity of genetic manipu-
lation of the walKR locus due to its essential nature. Thus, it has
remained unclear so far if an induced or a repressed WalKR
regulon might finally cause a development of antibiotic
resistance.27,32,58
Other amino acid exchanges observed in strain VC40 included
MprF(H224Y) that may alter the activity of this protein and thus
support daptomycin cross-resistance. In this context, mprF showed
higher expression levels in VISA compared with vancomycin-
susceptible S. aureus (VSSA) and decreased levels of mprF have
also been correlated with increased vancomycin susceptibil-
ity.27,59 – 61 Furthermore, increased expression or mutation of
mprF have also been reported to occur frequently in daptomycin-
non-susceptible S. aureus isolates54,57,62,63 and depletion of mprF
was described to restore daptomycin susceptibility in daptomycin-
resistant S. aureus isolates.64 Daptomycin cross-resistance of strain
VC40 might be further supported by RpoD(D201N), which is the
housekeeping sigma factor A (sA/s70). Noteworthy, mutations in
rpoB and rpoC have been correlated with reduced vancomycin
and daptomycin susceptibility in S. aureus54,57,65 and the VISA
strains Mu50 and JH9 also harbour SNPs in the rpoB and rpoD or
rpoB and rpoC genes, respectively.30,31
In conclusion, our results prove the important role of the histi-
dine kinase VraS in the physiology of the bacterial cell envelope. In
our study, the amino acid exchanges in VraS led to an increased
expression of the associated regulon, thereby mediating an
increased thickening of the cell wall, alterations in autolytic prop-
erties and eventually resulted in significantly higher MICs of the
glycopeptides vancomycin and teicoplanin as well as cross-
resistance to daptomycin. Thus, VraS can act as an important
switch to turn on antibiotic resistance in the S. aureus NCTC
8325 background.
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